Events Partner Content 4th Inflammasome Therapeutics Summit 2022 Only industry-led event on inflammasome-targeted drugs
News BMS bags first approval for myeloma CELMoD Zenbexus Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
